Braidwell LP Day One Biopharmaceuticals, Inc. Transaction History

Braidwell LP

$1.63 Billion
Q1 2025

A detailed history of Braidwell LP transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Braidwell LP holds 3,536,853 shares of DAWN stock, worth $23.5 Million. This represents 1.72% of its overall portfolio holdings.

Number of Shares

3,536,853

Previous 4,873,853 27.43%

Holding current value

$23.5 Million

Previous $61.8 Million 54.58%

% of portfolio

1.72%

Previous 3.46%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$7.93 - $13.21 $10.6 Million - $17.7 Million	-1,337,000 Reduced 27.43%	3,536,853 $28 Million
Q3 2024 Nov 14, 2024	BUY	$12.72 - $16.03 $23.4 Million - $29.5 Million	1,837,949 Added 60.54%	4,873,853 $67.9 Billion
Q2 2024 Aug 14, 2024	BUY	$12.03 - $17.69 $10.4 Million - $15.3 Million	862,200 Added 39.67%	3,035,904 $41.8 Billion
Q1 2024 May 15, 2024	SELL	$13.56 - $17.46 $27.7 Million - $35.7 Million	-2,041,869 Reduced 48.44%	2,173,704 $35.9 Billion
Q4 2023 Feb 14, 2024	BUY	$9.68 - $15.37 $4.84 Million - $7.69 Million	500,000 Added 13.46%	4,215,573 $61.5 Billion
Q3 2023 Nov 14, 2023	BUY	$11.22 - $14.86 $3.97 Million - $5.26 Million	353,760 Added 10.52%	3,715,573 $45.6 Billion
Q2 2023 Aug 14, 2023	BUY	$11.74 - $14.47 $2.37 Million - $2.92 Million	201,918 Added 6.39%	3,361,813 $40.1 Billion
Q1 2023 May 15, 2023	BUY	$12.75 - $23.41 $24.4 Million - $44.8 Million	1,913,356 Added 153.49%	3,159,895 $42.2 Billion
Q4 2022 Feb 14, 2023	BUY	$18.77 - $22.0 $23.4 Million - $27.4 Million	1,246,539 New	1,246,539 $26.8 Billion

Others Institutions Holding DAWN

# of Institutions

196

Shares Held

76.7M

Call Options Held

138K

Put Options Held

208K

View Full List

About Day One Biopharmaceuticals, Inc.

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $488M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

More about DAWN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.

Account